Fifteen years ago, folks in the industry were buzzing about RNAi the way they talk about CRISPR today. Then things went quiet for the technology, at least in the news. Until last year. In September of 2017, Alnylam Pharmaceuticals, the leader in the RNAi space, announced such positive phase III study results that most experts in the business expect an FDA approval soon. It will be the first for an RNAi drug.
Going Beyond the Liver with RNAi: Chris Anzalone of Arrowhead Pharma
www.mendelspod.com
Going Beyond the Liver with RNAi: Chris Anzalone of Arrowhead Pharma
Mendelspod Podcast
Offering a front row seat to the Century of Biology, veteran podcast host Theral Timpson interviews the who's who in genomics and genomic medicine.
Offering a front row seat to the Century of Biology, veteran podcast host Theral Timpson interviews the who's who in genomics and genomic medicine.Listen on
Substack App
RSS Feed
Appears in episode
Theral Timpson
Recent Episodes
Going Beyond the Liver with RNAi: Chris Anzalone of Arrowhead Pharma